Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer and Metastasis Reviews
Published in: Cancer and Metastasis Reviews 1/2022

Open Access 01-03-2022 | Breast Cancer

MicroRNAs as a clue to overcome breast cancer treatment resistance

Authors: Iris Garrido-Cano, Birlipta Pattanayak, Anna Adam-Artigues, Ana Lameirinhas, Sandra Torres-Ruiz, Eduardo Tormo, Raimundo Cervera, Pilar Eroles

Published in: Cancer and Metastasis Reviews | Issue 1/2022

Login to get access

Abstract

Breast cancer is the most frequent cancer in women worldwide. Despite the improvement in diagnosis and treatments, the rates of cancer relapse and resistance to therapies remain higher than desirable. Alterations in microRNAs have been linked to changes in critical processes related to cancer development and progression. Their involvement in resistance or sensitivity to breast cancer treatments has been documented by different in vivo and in vitro experiments. The most significant microRNAs implicated in modulating resistance to breast cancer therapies are summarized in this review. Resistance to therapy has been linked to cellular processes such as cell cycle, apoptosis, epithelial-to-mesenchymal transition, stemness phenotype, or receptor signaling pathways, and the role of microRNAs in their regulation has already been described. The modulation of specific microRNAs may modify treatment response and improve survival rates and cancer patients’ quality of life. As a result, a greater understanding of microRNAs, their targets, and the signaling pathways through which they act is needed. This information could be useful to design new therapeutic strategies, to reduce resistance to the available treatments, and to open the door to possible new clinical approaches.
Literature
1.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin.
2.
Abdalla F, Singh B, Bhat HK. MicroRNAs and gene regulation in breast cancer. J Biochem Mol Toxicol 2020; 34(11):e22567.
3.
Abolghasemi, M., Tehrani, S. S., Yousefi, T., Karimian, A., Mahmoodpoor, A., Ghamari, A., et al. (2020). MicroRNAs in breast cancer: Roles, functions, and mechanism of actions. Journal of Cellular Physiology, 235(6), 5008–5029.PubMedCrossRef
4.
Dastmalchi N, Safaralizadeh R, Baradaran B, Hosseinpourfeizi M, Baghbanzadeh A. An update review of deregulated tumor suppressive microRNAs and their contribution in various molecular subtypes of breast cancer. Gene 2020; 729:144301.
5.
Ding L, Gu H, Xiong X, Ao H, Cao J, Lin W, et al. MicroRNAs involved in carcinogenesis, prognosis, therapeutic resistance and applications in human triple-negative breast cancer. Cells 2019; 8(12).
6.
Fridrichova I, Zmetakova I. MicroRNAs contribute to breast cancer invasiveness. Cells 2019; 8(11).
7.
Kandettu A, Radhakrishnan R, Chakrabarty S, Sriharikrishnaa S, Kabekkodu SP. The emerging role of miRNA clusters in breast cancer progression. Biochim Biophys Acta Rev Cancer 2020; 1874(2):188413.
8.
Khalife, H., Skafi, N., Fayyad-Kazan, M., & Badran, B. (2020). MicroRNAs in breast cancer: New maestros defining the melody. Cancer Genetics, 246–247, 18–40.PubMedCrossRef
9.
Kudela E, Samec M, Koklesova L, Liskova A, Kubatka P, Kozubik E, et al. miRNA expression profiles in luminal A breast cancer-implications in biology, prognosis, and prediction of response to hormonal treatment. Int J Mol Sci 2020; 21(20).
10.
Loh HY, Norman BP, Lai KS, Rahman N, Alitheen NBM, Osman MA. The regulatory role of microRNAs in breast cancer. Int J Mol Sci 2019; 20(19).
11.
Mandujano-Tinoco, E. A., Garcia-Venzor, A., Melendez-Zajgla, J., & Maldonado, V. (2018). New emerging roles of microRNAs in breast cancer. Breast Cancer Research and Treatment, 171(2), 247–259.PubMedCrossRef
12.
Niu, L., Yang, W., Duan, L., Wang, X., Li, Y., Xu, C., et al. (2021). Biological implications and clinical potential of metastasis-related miRNA in colorectal cancer. Mol Ther Nucleic Acids, 23, 42–54.PubMedCrossRef
13.
Petri, B. J., & Klinge, C. M. (2020). Regulation of breast cancer metastasis signaling by miRNAs. Cancer and Metastasis Reviews, 39(3), 837–886.PubMedCrossRef
14.
Plantamura, I., Cosentino, G., & Cataldo, A. (2018). MicroRNAs and DNA-damaging drugs in breast cancer: Strength in numbers. Frontiers in Oncology, 8, 352.PubMedPubMedCentralCrossRef
15.
Saikia M, Paul S, Chakraborty S. Role of microRNA in forming breast carcinoma. Life Sci 2020; 259:118256.
16.
Zhang, Y., Xu, B., & Zhang, X. P. (2018). Effects of miRNAs on functions of breast cancer stem cells and treatment of breast cancer. Oncotargets and Therapy, 11, 4263–4270.PubMedPubMedCentralCrossRef
17.
Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: The next generation. Cell, 144(5), 646–674.CrossRef
18.
Aarts, M., Linardopoulos, S., & Turner, N. C. (2013). Tumour selective targeting of cell cycle kinases for cancer treatment. Current Opinion in Pharmacology, 13(4), 529–535.PubMedCrossRef
19.
Diaz-Moralli, S., Tarrado-Castellarnau, M., Miranda, A., & Cascante, M. (2013). Targeting cell cycle regulation in cancer therapy. Pharmacology & Therapeutics, 138(2), 255–271.CrossRef
20.
21.
Kastl, L., Brown, I., & Schofield, A. C. (2012). miRNA-34a is associated with docetaxel resistance in human breast cancer cells. Breast Cancer Research and Treatment, 131(2), 445–454.PubMedCrossRef
22.
Bao, C., Chen, J., Chen, D., Lu, Y., Lou, W., Ding, B., et al. (2020). MiR-93 suppresses tumorigenesis and enhances chemosensitivity of breast cancer via dual targeting E2F1 and CCND1. Cell Death & Disease, 11(8), 618.CrossRef
23.
Cataldo, A., Cheung, D. G., Balsari, A., Tagliabue, E., Coppola, V., Iorio, M. V., et al. (2016). miR-302b enhances breast cancer cell sensitivity to cisplatin by regulating E2F1 and the cellular DNA damage response. Oncotarget, 7(1), 786–797.PubMedCrossRef
24.
Wang, G., Ma, C., Shi, X., Guo, W., & Niu, J. (2019). miR-107 enhances the sensitivity of breast cancer cells to paclitaxel. Open Med (Wars), 14, 456–466.CrossRef
25.
Cittelly, D. M., Das, P. M., Spoelstra, N. S., Edgerton, S. M., Richer, J. K., Thor, A. D., et al. (2010). Downregulation of miR-342 is associated with tamoxifen resistant breast tumors. Molecular Cancer, 9, 317.PubMedPubMedCentralCrossRef
26.
Dou, D., Ren, X., Han, M., Xu, X., Ge, X., Gu, Y., et al. (2020). CircUBE2D2 (hsa_circ_0005728) promotes cell proliferation, metastasis and chemoresistance in triple-negative breast cancer by regulating miR-512-3p/CDCA3 axis. Cancer Cell International, 20, 454.PubMedPubMedCentralCrossRef
27.
Venturutti, L., Cordo Russo, R. I., Rivas, M. A., Mercogliano, M. F., Izzo, F., Oakley, R. H., et al. (2016). MiR-16 mediates trastuzumab and lapatinib response in ErbB-2-positive breast and gastric cancer via its novel targets CCNJ and FUBP1. Oncogene, 35(48), 6189–6202.PubMedPubMedCentralCrossRef
28.
Yang, W., Gu, J., Wang, X., Wang, Y., Feng, M., Zhou, D., et al. (2019). Inhibition of circular RNA CDR1as increases chemosensitivity of 5-FU-resistant BC cells through up-regulating miR-7. Journal of Cellular and Molecular Medicine, 23(5), 3166–3177.PubMedPubMedCentralCrossRef
29.
Ichikawa T, Sato F, Terasawa K, Tsuchiya S, Toi M, Tsujimoto G, et al. Trastuzumab produces therapeutic actions by upregulating miR-26a and miR-30b in breast cancer cells. PLoS One 2012; 7(2):e31422.
30.
Tormo, E., Adam-Artigues, A., Ballester, S., Pineda, B., Zazo, S., Gonzalez-Alonso, P., et al. (2017). The role of miR-26a and miR-30b in HER2+ breast cancer trastuzumab resistance and regulation of the CCNE2 gene. Science and Reports, 7, 41309.CrossRef
31.
Liu, J., Li, X., Wang, M., Xiao, G., Yang, G., Wang, H., et al. (2018). A miR-26a/E2F7 feedback loop contributes to tamoxifen resistance in ER-positive breast cancer. International Journal of Oncology, 53(4), 1601–1612.PubMed
32.
Tormo, E., Ballester, S., Adam-Artigues, A., Burgues, O., Alonso, E., Bermejo, B., et al. (2019). The miRNA-449 family mediates doxorubicin resistance in triple-negative breast cancer by regulating cell cycle factors. Science and Reports, 9(1), 5316.CrossRef
33.
Ward, A., Shukla, K., Balwierz, A., Soons, Z., Konig, R., Sahin, O., et al. (2014). MicroRNA-519a is a novel oncomir conferring tamoxifen resistance by targeting a network of tumour-suppressor genes in ER+ breast cancer. The Journal of Pathology, 233(4), 368–379.PubMedCrossRef
34.
Wang, B., Li, D., Filkowski, J., Rodriguez-Juarez, R., Storozynsky, Q., Malach, M., et al. (2018). A dual role of miR-22 modulated by RelA/p65 in resensitizing fulvestrant-resistant breast cancer cells to fulvestrant by targeting FOXP1 and HDAC4 and constitutive acetylation of p53 at Lys382. Oncogenesis, 7(7), 54.PubMedPubMedCentralCrossRef
35.
Jiang, H., Cheng, L., Hu, P., & Liu, R. (2018). MicroRNA663b mediates TAM resistance in breast cancer by modulating TP73 expression. Molecular Medicine Reports, 18(1), 1120–1126.PubMed
36.
Miller, T. E., Ghoshal, K., Ramaswamy, B., Roy, S., Datta, J., Shapiro, C. L., et al. (2008). MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. Journal of Biological Chemistry, 283(44), 29897–29903.CrossRef
37.
Wang, S., Oh, D. Y., Leventaki, V., Drakos, E., Zhang, R., Sahin, A. A., et al. (2019). MicroRNA-17 acts as a tumor chemosensitizer by targeting JAB1/CSN5 in triple-negative breast cancer. Cancer Letters, 465, 12–23.PubMedCrossRef
38.
Zhang, H., Zhao, B., Wang, X., Zhang, F., & Yu, W. (2019). LINC00511 knockdown enhances paclitaxel cytotoxicity in breast cancer via regulating miR-29c/CDK6 axis. Life Sciences, 228, 135–144.PubMedCrossRef
39.
Zhang, W., Jiang, H., Chen, Y., & Ren, F. (2019). Resveratrol chemosensitizes adriamycin-resistant breast cancer cells by modulating miR-122-5p. Journal of Cellular Biochemistry, 120(9), 16283–16292.PubMedCrossRef
40.
Citron, F., Segatto, I., Vinciguerra, G. L. R., Musco, L., Russo, F., Mungo, G., et al. (2020). Downregulation of miR-223 expression is an early event during mammary transformation and confers resistance to CDK4/6 inhibitors in luminal breast cancer. Cancer Research, 80(5), 1064–1077.PubMedCrossRef
41.
Goodarzi, A. A., & Jeggo, P. A. (2013). The repair and signaling responses to DNA double-strand breaks. Advances in Genetics, 82, 1–45.PubMedCrossRef
42.
Falck, J., Coates, J., & Jackson, S. P. (2005). Conserved modes of recruitment of ATM, ATR and DNA-PKcs to sites of DNA damage. Nature, 434(7033), 605–611.PubMedCrossRef
43.
Wu, J., Lu, L. Y., & Yu, X. (2010). The role of BRCA1 in DNA damage response. Protein & Cell, 1(2), 117–123.CrossRef
44.
Moskwa, P., Buffa, F. M., Pan, Y., Panchakshari, R., Gottipati, P., Muschel, R. J., et al. (2011). miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors. Molecular Cell, 41(2), 210–220.PubMedCrossRef
45.
He, X., Xiao, X., Dong, L., Wan, N., Zhou, Z., Deng, H., et al. (2015). MiR-218 regulates cisplatin chemosensitivity in breast cancer by targeting BRCA1. Tumour Biology, 36(3), 2065–2075.PubMedCrossRef
46.
Xu, X., Lv, Y. G., Yan, C. Y., Yi, J., & Ling, R. (2016). Enforced expression of hsa-miR-125a-3p in breast cancer cells potentiates docetaxel sensitivity via modulation of BRCA1 signaling. Biochemical and Biophysical Research Communications, 479(4), 893–900.PubMedCrossRef
47.
Chen SM, Chou WC, Hu LY, Hsiung CN, Chu HW, Huang YL, et al. The effect of microRNA-124 overexpression on anti-tumor drug sensitivity. PLoS One 2015; 10(6):e0128472.
48.
Bisso, A., Faleschini, M., Zampa, F., Capaci, V., De Santa, J., Santarpia, L., et al. (2013). Oncogenic miR-181a/b affect the DNA damage response in aggressive breast cancer. Cell Cycle, 12(11), 1679–1687.PubMedPubMedCentralCrossRef
49.
Xu, S., Zhao, C., Jia, Z., Wang, X., Han, Y., & Yang, Z. (2017). Down-regulation of PARP1 by miR-891b sensitizes human breast cancer cells to alkylating chemotherapeutic drugs. Archives of Gynecology and Obstetrics, 296(3), 543–549.PubMedCrossRef
50.
Mei, Z., Su, T., Ye, J., Yang, C., Zhang, S., & Xie, C. (2015). The miR-15 family enhances the radiosensitivity of breast cancer cells by targeting G2 checkpoints. Radiation Research, 183(2), 196–207.PubMedCrossRef
51.
Lu, X., Liu, R., Wang, M., Kumar, A. K., Pan, F., He, L., et al. (2020). MicroRNA-140 impedes DNA repair by targeting FEN1 and enhances chemotherapeutic response in breast cancer. Oncogene, 39(1), 234–247.PubMedCrossRef
52.
Lin, S., Yu, L., Song, X., Bi, J., Jiang, L., Wang, Y., et al. (2019). Intrinsic adriamycin resistance in p53-mutated breast cancer is related to the miR-30c/FANCF/REV1-mediated DNA damage response. Cell Death & Disease, 10(9), 666.CrossRef
53.
Bialik, S., Zalckvar, E., Ber, Y., Rubinstein, A. D., & Kimchi, A. (2010). Systems biology analysis of programmed cell death. Trends in Biochemical Sciences, 35(10), 556–564.PubMedCrossRef
54.
Nishida, K., Yamaguchi, O., & Otsu, K. (2008). Crosstalk between autophagy and apoptosis in heart disease. Circulation Research, 103(4), 343–351.PubMedCrossRef
55.
Llambi, F., & Green, D. R. (2011). Apoptosis and oncogenesis: Give and take in the BCL-2 family. Current Opinion in Genetics & Development, 21(1), 12–20.CrossRef
56.
Benchimol, S. (2001). p53-dependent pathways of apoptosis. Cell Death and Differentiation, 8(11), 1049–1051.PubMedCrossRef
57.
Bratton, S. B., Walker, G., Srinivasula, S. M., Sun, X. M., Butterworth, M., Alnemri, E. S., et al. (2001). Recruitment, activation and retention of caspases-9 and -3 by Apaf-1 apoptosome and associated XIAP complexes. EMBO Journal, 20(5), 998–1009.CrossRef
58.
Chen, S., Rehman, S. K., Zhang, W., Wen, A., Yao, L., & Zhang, J. (2010). Autophagy is a therapeutic target in anticancer drug resistance. Biochimica et Biophysica Acta, 1806(2), 220–229.PubMed
59.
Hara, T., Takamura, A., Kishi, C., Iemura, S., Natsume, T., Guan, J. L., et al. (2008). FIP200, a ULK-interacting protein, is required for autophagosome formation in mammalian cells. Journal of Cell Biology, 181(3), 497–510.CrossRef
60.
Lee, J. T., Jr., & McCubrey, J. A. (2002). Targeting the Raf kinase cascade in cancer therapy–novel molecular targets and therapeutic strategies. Expert Opinion on Therapeutic Targets, 6(6), 659–678.PubMedCrossRef
61.
Ji, Y., Di, W., Yang, Q., Lu, Z., Cai, W., & Wu, J. (2015). Inhibition of autophagy increases proliferation inhibition and apoptosis induced by the PI3K/mTOR inhibitor NVP-BEZ235 in breast cancer cells. Clinical Laboratory, 61(8), 1043–1051.PubMed
62.
63.
Kim, Y. S., Morgan, M. J., Choksi, S., & Liu, Z. G. (2007). TNF-induced activation of the Nox1 NADPH oxidase and its role in the induction of necrotic cell death. Molecular Cell, 26(5), 675–687.PubMedCrossRef
64.
Strasser, A., & Vaux, D. L. (2020). Cell death in the origin and treatment of cancer. Molecular Cell, 78(6), 1045–1054.PubMedCrossRef
65.
Zhou, M., Liu, Z., Zhao, Y., Ding, Y., Liu, H., Xi, Y., et al. (2010). MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression. Journal of Biological Chemistry, 285(28), 21496–21507.CrossRef
66.
Xiang, F., Fan, Y., Ni, Z., Liu, Q., Zhu, Z., Chen, Z., et al. (2019). Ursolic acid reverses the chemoresistance of breast cancer cells to paclitaxel by targeting MiRNA-149-5p/MyD88. Frontiers in Oncology, 9, 501.PubMedPubMedCentralCrossRef
67.
Cittelly, D. M., Das, P. M., Salvo, V. A., Fonseca, J. P., Burow, M. E., & Jones, F. E. (2010). Oncogenic HER2{Delta}16 suppresses miR-15a/16 and deregulates BCL-2 to promote endocrine resistance of breast tumors. Carcinogenesis, 31(12), 2049–2057.PubMedPubMedCentralCrossRef
68.
O’Brien, K., Lowry, M. C., Corcoran, C., Martinez, V. G., Daly, M., Rani, S., et al. (2015). miR-134 in extracellular vesicles reduces triple-negative breast cancer aggression and increases drug sensitivity. Oncotarget, 6(32), 32774–32789.PubMedPubMedCentralCrossRef
69.
Chen, L., & Bourguignon, L. Y. (2014). Hyaluronan-CD44 interaction promotes c-Jun signaling and miRNA21 expression leading to Bcl-2 expression and chemoresistance in breast cancer cells. Molecular Cancer, 13, 52.PubMedPubMedCentralCrossRef
70.
Korner, C., Keklikoglou, I., Bender, C., Worner, A., Munstermann, E., & Wiemann, S. (2013). MicroRNA-31 sensitizes human breast cells to apoptosis by direct targeting of protein kinase C epsilon (PKCepsilon). Journal of Biological Chemistry, 288(12), 8750–8761.CrossRef
71.
Li, Z. H., Weng, X., Xiong, Q. Y., Tu, J. H., Xiao, A., Qiu, W., et al. (2017). miR-34a expression in human breast cancer is associated with drug resistance. Oncotarget, 8(63), 106270–106282.PubMedPubMedCentralCrossRef
72.
Xie, X., Hu, Y., Xu, L., Fu, Y., Tu, J., Zhao, H., et al. (2015). The role of miR-125b-mitochondria-caspase-3 pathway in doxorubicin resistance and therapy in human breast cancer. Tumour Biology, 36(9), 7185–7194.PubMedCrossRef
73.
Chen, X., Wang, Y. W., Xing, A. Y., Xiang, S., Shi, D. B., Liu, L., et al. (2016). Suppression of SPIN1-mediated PI3K-Akt pathway by miR-489 increases chemosensitivity in breast cancer. The Journal of Pathology, 239(4), 459–472.PubMedCrossRef
74.
Yang, G., Wu, D., Zhu, J., Jiang, O., Shi, Q., Tian, J., et al. (2013). Upregulation of miR-195 increases the sensitivity of breast cancer cells to Adriamycin treatment through inhibition of Raf-1. Oncology Reports, 30(2), 877–889.PubMedCrossRef
75.
Gu, X., Li, J. Y., Guo, J., Li, P. S., & Zhang, W. H. (2015). Influence of MiR-451 on drug resistances of paclitaxel-resistant breast cancer cell line. Medical Science Monitor, 21, 3291–3297.PubMedPubMedCentralCrossRef
76.
Hong, T., Ding, J., & Li, W. (2019). miR-7 reverses breast cancer resistance to chemotherapy by targeting MRP1 and BCL2. Oncotargets and Therapy, 12, 11097–11105.PubMedPubMedCentralCrossRef
77.
You, F., Luan, H., Sun, D., Cui, T., Ding, P., Tang, H., et al. (2019). miRNA-106a promotes breast cancer cell proliferation, clonogenicity, migration, and invasion through inhibiting apoptosis and chemosensitivity. DNA and Cell Biology, 38(2), 198–207.PubMedCrossRef
78.
Manvati, S., Mangalhara, K. C., Kalaiarasan, P., Srivastava, N., & Bamezai, R. N. (2015). miR-24-2 regulates genes in survival pathway and demonstrates potential in reducing cellular viability in combination with docetaxel. Gene, 567(2), 217–224.PubMedCrossRef
79.
Long J, Ji Z, Jiang K, Wang Z, Meng G. miR-193b modulates resistance to doxorubicin in human breast cancer cells by downregulating MCL-1. Biomed Res Int 2015; 2015:373574.
80.
Xie, Q., Wang, S., Zhao, Y., Zhang, Z., Qin, C., & Yang, X. (2017). MiR-519d impedes cisplatin-resistance in breast cancer stem cells by down-regulating the expression of MCL-1. Oncotarget, 8(13), 22003–22013.PubMedPubMedCentralCrossRef
81.
Aakko, S., Straume, A. H., Birkeland, E. E., Chen, P., Qiao, X., Lonning, P. E., et al. (2019). MYC-induced miR-203b-3p and miR-203a-3p control Bcl-xL expression and paclitaxel sensitivity in tumor cells. Transl Oncol, 12(1), 170–179.PubMedCrossRef
82.
Yue J, Lopez JM. Understanding MAPK signaling pathways in apoptosis. Int J Mol Sci 2020; 21(7).
83.
Mi, H., Wang, X., Wang, F., Li, L., Zhu, M., Wang, N., et al. (2018). miR-381 induces sensitivity of breast cancer cells to doxorubicin by inactivation of MAPK signaling via FYN. European Journal of Pharmacology, 839, 66–75.PubMedCrossRef
84.
Fang, Y., Shen, H., Cao, Y., Li, H., Qin, R., Chen, Q., et al. (2014). Involvement of miR-30c in resistance to doxorubicin by regulating YWHAZ in breast cancer cells. Brazilian Journal of Medical and Biological Research, 47(1), 60–69.PubMedPubMedCentralCrossRef
85.
Han, X., Li, Q., Liu, C., Wang, C., & Li, Y. (2019). Overexpression miR-24-3p repressed Bim expression to confer tamoxifen resistance in breast cancer. Journal of Cellular Biochemistry, 120(8), 12966–12976.PubMedCrossRef
86.
Ye, Z., Hao, R., Cai, Y., Wang, X., & Huang, G. (2016). Knockdown of miR-221 promotes the cisplatin-inducing apoptosis by targeting the BIM-Bax/Bak axis in breast cancer. Tumour Biology, 37(4), 4509–4515.PubMedCrossRef
87.
Dai H, Xu LY, Qian Q, Zhu QW, Chen WX. MicroRNA-222 promotes drug resistance to doxorubicin in breast cancer via regulation of miR-222/bim pathway. Biosci Rep 2019; 39(7).
88.
Zheng, Y., Lv, X., Wang, X., Wang, B., Shao, X., Huang, Y., et al. (2016). MiR-181b promotes chemoresistance in breast cancer by regulating Bim expression. Oncology Reports, 35(2), 683–690.PubMedCrossRef
89.
Zhang, Y., He, Y., Lu, L. L., Zhou, Z. Y., Wan, N. B., Li, G. P., et al. (2019). miRNA-192-5p impacts the sensitivity of breast cancer cells to doxorubicin via targeting peptidylprolyl isomerase A. Kaohsiung Journal of Medical Sciences, 35(1), 17–23.CrossRef
90.
Wang, X., & Zhu, J. (2018). Mir-1307 regulates cisplatin resistance by targeting Mdm4 in breast cancer expressing wild type P53. Thorac Cancer, 9(6), 676–683.PubMedPubMedCentralCrossRef
91.
Sharma, S., Nagpal, N., Ghosh, P. C., & Kulshreshtha, R. (2017). P53-miR-191-SOX4 regulatory loop affects apoptosis in breast cancer. RNA, 23(8), 1237–1246.PubMedPubMedCentralCrossRef
92.
Kopp F, Oak PS, Wagner E, Roidl A. miR-200c sensitizes breast cancer cells to doxorubicin treatment by decreasing TrkB and Bmi1 expression. PLoS One 2012; 7(11):e50469.
93.
Zhu, Y., Yu, F., Jiao, Y., Feng, J., Tang, W., Yao, H., et al. (2011). Reduced miR-128 in breast tumor-initiating cells induces chemotherapeutic resistance via Bmi-1 and ABCC5. Clinical Cancer Research, 17(22), 7105–7115.PubMedCrossRef
94.
Wu, G., Zhou, W., Pan, X., Sun, Y., Xu, H., Shi, P., et al. (2018). miR-100 reverses cisplatin resistance in breast cancer by suppressing HAX-1. Cellular Physiology and Biochemistry, 47(5), 2077–2087.PubMedCrossRef
95.
He, H., Tian, W., Chen, H., & Jiang, K. (2016). MiR-944 functions as a novel oncogene and regulates the chemoresistance in breast cancer. Tumour Biology, 37(2), 1599–1607.PubMedCrossRef
96.
Zhang D, Shi Z, Li M, Mi J. Hypoxia-induced miR-424 decreases tumor sensitivity to chemotherapy by inhibiting apoptosis. Cell Death Dis 2014; 5:e1301.
97.
Tao, L., Wu, Y. Q., & Zhang, S. P. (2019). MiR-21-5p enhances the progression and paclitaxel resistance in drug-resistant breast cancer cell lines by targeting PDCD4. Neoplasma, 66(5), 746–755.PubMedCrossRef
98.
Deng, Y. W., Hao, W. J., Li, Y. W., Li, Y. X., Zhao, B. C., & Lu, D. (2018). Hsa-miRNA-143-3p reverses multidrug resistance of triple-negative breast cancer by inhibiting the expression of its target protein cytokine-induced apoptosis inhibitor 1 in vivo. Journal of Breast Cancer, 21(3), 251–258.PubMedPubMedCentralCrossRef
99.
Duan, W. J., Bi, P. D., Ma, Y., Liu, N. Q., & Zhen, X. (2020). MiR-512-3p regulates malignant tumor behavior and multi-drug resistance in breast cancer cells via targeting Livin. Neoplasma, 67(1), 102–110.PubMedCrossRef
100.
Zheng, S., Li, M., Miao, K., & Xu, H. (2020). lncRNA GAS5-promoted apoptosis in triple-negative breast cancer by targeting miR-378a-5p/SUFU signaling. Journal of Cellular Biochemistry, 121(3), 2225–2235.PubMedCrossRef
101.
Yu, X., Luo, A., Liu, Y., Wang, S., Li, Y., Shi, W., et al. (2015). MiR-214 increases the sensitivity of breast cancer cells to tamoxifen and fulvestrant through inhibition of autophagy. Molecular Cancer, 14, 208.PubMedPubMedCentralCrossRef
102.
Liu, Z. R., Song, Y., Wan, L. H., Zhang, Y. Y., & Zhou, L. M. (2016). Over-expression of miR-451a can enhance the sensitivity of breast cancer cells to tamoxifen by regulating 14-3-3zeta, estrogen receptor alpha, and autophagy. Life Sciences, 149, 104–113.PubMedCrossRef
103.
Lu, M., Ding, K., Zhang, G., Yin, M., Yao, G., Tian, H., et al. (2015). MicroRNA-320a sensitizes tamoxifen-resistant breast cancer cells to tamoxifen by targeting ARPP-19 and ERRgamma. Science and Reports, 5, 8735.CrossRef
104.
Ueda, S., Takanashi, M., Sudo, K., Kanekura, K., & Kuroda, M. (2020). miR-27a ameliorates chemoresistance of breast cancer cells by disruption of reactive oxygen species homeostasis and impairment of autophagy. Laboratory Investigation, 100(6), 863–873.PubMedCrossRef
105.
Han, M., Hu, J., Lu, P., Cao, H., Yu, C., Li, X., et al. (2020). Exosome-transmitted miR-567 reverses trastuzumab resistance by inhibiting ATG5 in breast cancer. Cell Death & Disease, 11(1), 43.CrossRef
106.
Shi Y, Gong W, Lu L, Wang Y, Ren J. Upregulation of miR-129–5p increases the sensitivity to Taxol through inhibiting HMGB1-mediated cell autophagy in breast cancer MCF-7 cells. Braz J Med Biol Res 2019; 52(11):e8657.
107.
Hsu, J. L., & Hung, M. C. (2016). The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer. Cancer and Metastasis Reviews, 35(4), 575–588.PubMedCrossRef
108.
Yarden, Y., & Sliwkowski, M. X. (2001). Untangling the ErbB signalling network. Nature Reviews Molecular Cell Biology, 2(2), 127–137.PubMedCrossRef
109.
Sergina, N. V., & Moasser, M. M. (2007). The HER family and cancer: Emerging molecular mechanisms and therapeutic targets. Trends in Molecular Medicine, 13(12), 527–534.PubMedPubMedCentralCrossRef
110.
Gomez, G. G., Wykosky, J., Zanca, C., Furnari, F. B., & Cavenee, W. K. (2013). Therapeutic resistance in cancer: MicroRNA regulation of EGFR signaling networks. Cancer Biology & Medicine, 10(4), 192–205.
111.
112.
Masuda, H., Zhang, D., Bartholomeusz, C., Doihara, H., Hortobagyi, G. N., & Ueno, N. T. (2012). Role of epidermal growth factor receptor in breast cancer. Breast Cancer Research and Treatment, 136(2), 331–345.PubMedCrossRef
113.
Huang, Q., Wu, Y. Y., Xing, S. J., & Yu, Z. W. (2019). Effect of miR-7 on resistance of breast cancer cells to adriamycin via regulating EGFR/PI3K signaling pathway. European Review for Medical and Pharmacological Sciences, 23(12), 5285–5292.PubMed
114.
Li, M., Yang, J., Zhang, L., Tu, S., Zhou, X., Tan, Z., et al. (2019). A low-molecular-weight compound exerts anticancer activity against breast and lung cancers by disrupting EGFR/Eps8 complex formation. Journal of Experimental & Clinical Cancer Research, 38(1), 211.CrossRef
115.
Ma, Y., Bu, D., Long, J., Chai, W., & Dong, J. (2019). LncRNA DSCAM-AS1 acts as a sponge of miR-137 to enhance Tamoxifen resistance in breast cancer. Journal of Cellular Physiology, 234(3), 2880–2894.PubMedCrossRef
116.
He, M., Jin, Q., Chen, C., Liu, Y., Ye, X., Jiang, Y., et al. (2019). The miR-186-3p/EREG axis orchestrates tamoxifen resistance and aerobic glycolysis in breast cancer cells. Oncogene, 38(28), 5551–5565.PubMedCrossRef
117.
Corcoran, C., Rani, S., Breslin, S., Gogarty, M., Ghobrial, I. M., Crown, J., et al. (2014). miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancer. Molecular Cancer, 13, 71.PubMedPubMedCentralCrossRef
118.
Ye, X. M., Zhu, H. Y., Bai, W. D., Wang, T., Wang, L., Chen, Y., et al. (2014). Epigenetic silencing of miR-375 induces trastuzumab resistance in HER2-positive breast cancer by targeting IGF1R. BMC Cancer, 14, 134.PubMedPubMedCentralCrossRef
119.
Zhang H, Zheng XD, Zeng XH, Li L, Zhou Q. MiR-520b inhibits IGF-1R to increase doxorubicin sensitivity and promote cell apoptosis in breast cancer. Yakugaku Zasshi 2020.
120.
Oksvold, M. P., Huitfeldt, H. S., & Langdon, W. Y. (2004). Identification of 14-3-3zeta as an EGF receptor interacting protein. FEBS Letters, 569(1–3), 207–210.PubMedCrossRef
121.
Frasor, J., Chang, E. C., Komm, B., Lin, C. Y., Vega, V. B., Liu, E. T., et al. (2006). Gene expression preferentially regulated by tamoxifen in breast cancer cells and correlations with clinical outcome. Cancer Research, 66(14), 7334–7340.PubMedCrossRef
122.
Bergamaschi, A., & Katzenellenbogen, B. S. (2012). Tamoxifen downregulation of miR-451 increases 14-3-3zeta and promotes breast cancer cell survival and endocrine resistance. Oncogene, 31(1), 39–47.PubMedCrossRef
123.
Cooke, T., Reeves, J., Lanigan, A., & Stanton, P. (2001). HER2 as a prognostic and predictive marker for breast cancer. Annals of Oncology, 12(Suppl 1), S23-28.PubMedCrossRef
124.
Pernas, S., & Tolaney, S. M. (2019). HER2-positive breast cancer: New therapeutic frontiers and overcoming resistance. Ther Adv Med Oncol, 11, 1758835919833519.PubMedPubMedCentralCrossRef
125.
Tan, S., Ding, K., Chong, Q. Y., Zhao, J., Liu, Y., Shao, Y., et al. (2017). Post-transcriptional regulation of ERBB2 by miR26a/b and HuR confers resistance to tamoxifen in estrogen receptor-positive breast cancer cells. Journal of Biological Chemistry, 292(33), 13551–13564.CrossRef
126.
Fang, C., Zhao, Y., & Guo, B. (2013). MiR-199b-5p targets HER2 in breast cancer cells. Journal of Cellular Biochemistry, 114(7), 1457–1463.PubMedCrossRef
127.
Sajadimajd, S., Yazdanparast, R., & Akram, S. (2016). Involvement of Numb-mediated HIF-1alpha inhibition in anti-proliferative effect of PNA-antimiR-182 in trastuzumab-sensitive and -resistant SKBR3 cells. Tumour Biology, 37(4), 5413–5426.PubMedCrossRef
128.
Bai, W. D., Ye, X. M., Zhang, M. Y., Zhu, H. Y., Xi, W. J., Huang, X., et al. (2014). MiR-200c suppresses TGF-beta signaling and counteracts trastuzumab resistance and metastasis by targeting ZNF217 and ZEB1 in breast cancer. International Journal of Cancer, 135(6), 1356–1368.PubMedCrossRef
129.
Mitra, D., Brumlik, M. J., Okamgba, S. U., Zhu, Y., Duplessis, T. T., Parvani, J. G., et al. (2009). An oncogenic isoform of HER2 associated with locally disseminated breast cancer and trastuzumab resistance. Molecular Cancer Therapeutics, 8(8), 2152–2162.PubMedCrossRef
130.
Huynh FC, Jones FE. MicroRNA-7 inhibits multiple oncogenic pathways to suppress HER2Delta16 mediated breast tumorigenesis and reverse trastuzumab resistance. PLoS One 2014; 9(12):e114419.
131.
Baselga, J., & Swain, S. M. (2009). Novel anticancer targets: Revisiting ERBB2 and discovering ERBB3. Nature Reviews Cancer, 9(7), 463–475.PubMedCrossRef
132.
Bieche, I., Onody, P., Tozlu, S., Driouch, K., Vidaud, M., & Lidereau, R. (2003). Prognostic value of ERBB family mRNA expression in breast carcinomas. International Journal of Cancer, 106(5), 758–765.PubMedCrossRef
133.
Wu, H., Zhu, S., & Mo, Y. Y. (2009). Suppression of cell growth and invasion by miR-205 in breast cancer. Cell Research, 19(4), 439–448.PubMedCrossRef
134.
Iorio, M. V., Casalini, P., Piovan, C., Di Leva, G., Merlo, A., Triulzi, T., et al. (2009). microRNA-205 regulates HER3 in human breast cancer. Cancer Research, 69(6), 2195–2200.PubMedCrossRef
135.
Cataldo, A., Piovan, C., Plantamura, I., D’Ippolito, E., Camelliti, S., Casalini, P., et al. (2018). MiR-205 as predictive biomarker and adjuvant therapeutic tool in combination with trastuzumab. Oncotarget, 9(46), 27920–27928.PubMedPubMedCentralCrossRef
136.
Cai, Y., Yan, X., Zhang, G., Zhao, W., & Jiao, S. (2016). MicroRNA-205 increases the sensitivity of docetaxel in breast cancer. Oncology Letters, 11(2), 1105–1109.PubMedCrossRef
137.
Lyu, H., Huang, J., He, Z., & Liu, B. (2018). Targeting of HER3 with functional cooperative miRNAs enhances therapeutic activity in HER2-overexpressing breast cancer cells. Biol Proced Online, 20, 16.PubMedPubMedCentralCrossRef
138.
De Cola A, Volpe S, Budani MC, Ferracin M, Lattanzio R, Turdo A, et al. miR-205–5p-mediated downregulation of ErbB/HER receptors in breast cancer stem cells results in targeted therapy resistance. Cell Death Dis 2015; 6:e1823.
139.
De Cola, A., Lamolinara, A., Lanuti, P., Rossi, C., Iezzi, M., Marchisio, M., et al. (2018). MiR-205-5p inhibition by locked nucleic acids impairs metastatic potential of breast cancer cells. Cell Death & Disease, 9(8), 821.CrossRef
140.
Zhao, Z., Li, R., Sha, S., Wang, Q., Mao, W., & Liu, T. (2014). Targeting HER3 with miR-450b-3p suppresses breast cancer cells proliferation. Cancer Biology & Therapy, 15(10), 1404–1412.CrossRef
141.
Han G, Qiu N, Luo K, Liang H, Li H. Downregulation of miroRNA-141 mediates acquired resistance to trastuzumab and is associated with poor outcome in breast cancer by upregulating the expression of ERBB4. J Cell Biochem 2019.
142.
143.
Musgrove, E. A., & Sutherland, R. L. (2009). Biological determinants of endocrine resistance in breast cancer. Nature Reviews Cancer, 9(9), 631–643.PubMedCrossRef
144.
Miller TW. Endocrine resistance: What do we know? Am Soc Clin Oncol Educ Book 2013.
145.
Yamashita, H., Yando, Y., Nishio, M., Zhang, Z., Hamaguchi, M., Mita, K., et al. (2006). Immunohistochemical evaluation of hormone receptor status for predicting response to endocrine therapy in metastatic breast cancer. Breast Cancer, 13(1), 74–83.PubMedCrossRef
146.
Egeland, N. G., Lunde, S., Jonsdottir, K., Lende, T. H., Cronin-Fenton, D., Gilje, B., et al. (2015). The role of microRNAs as predictors of response to tamoxifen treatment in breast cancer patients. International Journal of Molecular Sciences, 16(10), 24243–24275.PubMedPubMedCentralCrossRef
147.
Ahmad, A., Ginnebaugh, K. R., Yin, S., Bollig-Fischer, A., Reddy, K. B., & Sarkar, F. H. (2015). Functional role of miR-10b in tamoxifen resistance of ER-positive breast cancer cells through down-regulation of HDAC4. BMC Cancer, 15, 540.PubMedPubMedCentralCrossRef
148.
Leong, H., Sloan, J. R., Nash, P. D., & Greene, G. L. (2005). Recruitment of histone deacetylase 4 to the N-terminal region of estrogen receptor alpha. Molecular Endocrinology, 19(12), 2930–2942.PubMedCrossRef
149.
Liu, S. S., Li, Y., Zhang, H., Zhang, D., Zhang, X. B., Wang, X., et al. (2020). The ERalpha-miR-575-p27 feedback loop regulates tamoxifen sensitivity in ER-positive Breast Cancer. Theranostics, 10(23), 10729–10742.PubMedPubMedCentralCrossRef
150.
Manavalan, T. T., Teng, Y., Appana, S. N., Datta, S., Kalbfleisch, T. S., Li, Y., et al. (2011). Differential expression of microRNA expression in tamoxifen-sensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells. Cancer Letters, 313(1), 26–43.PubMedPubMedCentralCrossRef
151.
Wei, Y., Lai, X., Yu, S., Chen, S., Ma, Y., Zhang, Y., et al. (2014). Exosomal miR-221/222 enhances tamoxifen resistance in recipient ER-positive breast cancer cells. Breast Cancer Research and Treatment, 147(2), 423–431.PubMedCrossRef
152.
Martin, E. C., Conger, A. K., Yan, T. J., Hoang, V. T., Miller, D. F., Buechlein, A., et al. (2017). MicroRNA-335-5p and -3p synergize to inhibit estrogen receptor alpha expression and promote tamoxifen resistance. FEBS Letters, 591(2), 382–392.PubMedPubMedCentralCrossRef
153.
He, Y. J., Wu, J. Z., Ji, M. H., Ma, T., Qiao, E. Q., Ma, R., et al. (2013). miR-342 is associated with estrogen receptor-alpha expression and response to tamoxifen in breast cancer. Experimental and Therapeutic Medicine, 5(3), 813–818.PubMedPubMedCentralCrossRef
154.
Ljepoja, B., Garcia-Roman, J., Sommer, A. K., Wagner, E., & Roidl, A. (2019). MiRNA-27a sensitizes breast cancer cells to treatment with selective estrogen receptor modulators. Breast, 43, 31–38.PubMedCrossRef
155.
Li, X., Mertens-Talcott, S. U., Zhang, S., Kim, K., Ball, J., & Safe, S. (2010). MicroRNA-27a indirectly regulates estrogen receptor alpha expression and hormone responsiveness in MCF-7 breast cancer cells. Endocrinology, 151(6), 2462–2473.PubMedPubMedCentralCrossRef
156.
Li, Y., Zhou, Y., Mao, F., Shen, S., Zhao, B., Xu, Y., et al. (2020). miR-452 reverses abnormal glycosylation modification of ERalpha and estrogen resistance in TNBC (triple-negative breast cancer) through targeting UGT1A1. Frontiers in Oncology, 10, 1509.PubMedPubMedCentralCrossRef
157.
Sarkar S, Ghosh A, Banerjee S, Maity G, Das A, Larson MA, et al. CCN5/WISP-2 restores ER- proportional, variant in normal and neoplastic breast cells and sensitizes triple negative breast cancer cells to tamoxifen. Oncogenesis 2017; 6(5):e340.
158.
Zhang W, Wu M, Chong QY, Zhang M, Zhang X, Hu L, et al. Loss of estrogen-regulated MIR135A1 at 3p21.1 promotes tamoxifen resistance in breast cancer. Cancer Res 2018; 78(17):4915–4928.
159.
Osborne, C. K., Bardou, V., Hopp, T. A., Chamness, G. C., Hilsenbeck, S. G., Fuqua, S. A., et al. (2003). Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. Journal of the National Cancer Institute, 95(5), 353–361.PubMedCrossRef
160.
Eedunuri, V. K., Rajapakshe, K., Fiskus, W., Geng, C., Chew, S. A., Foley, C., et al. (2015). miR-137 targets p160 steroid receptor coactivators SRC1, SRC2, and SRC3 and inhibits cell proliferation. Molecular Endocrinology, 29(8), 1170–1183.PubMedPubMedCentralCrossRef
161.
Cui, J., Yang, Y., Li, H., Leng, Y., Qian, K., Huang, Q., et al. (2015). MiR-873 regulates ERalpha transcriptional activity and tamoxifen resistance via targeting CDK3 in breast cancer cells. Oncogene, 34(30), 3895–3907.PubMedCrossRef
162.
Zhang X, Zhang B, Zhang P, Lian L, Li L, Qiu Z, et al. Norcantharidin regulates ERalpha signaling and tamoxifen resistance via targeting miR-873/CDK3 in breast cancer cells. PLoS One 2019; 14(5):e0217181.
163.
Miricescu D, Totan A, Stanescu S, II, Badoiu SC, Stefani C, Greabu M. PI3K/AKT/mTOR signaling pathway in breast cancer: From molecular landscape to clinical aspects. Int J Mol Sci 2020; 22(1).
164.
Alvarez-Garcia, V., Tawil, Y., Wise, H. M., & Leslie, N. R. (2019). Mechanisms of PTEN loss in cancer: It’s all about diversity. Seminars in Cancer Biology, 59, 66–79.PubMedCrossRef
165.
Liang, Z., Li, Y., Huang, K., Wagar, N., & Shim, H. (2011). Regulation of miR-19 to breast cancer chemoresistance through targeting PTEN. Pharmaceutical Research, 28(12), 3091–3100.PubMedPubMedCentralCrossRef
166.
Wang, Z. X., Lu, B. B., Wang, H., Cheng, Z. X., & Yin, Y. M. (2011). MicroRNA-21 modulates chemosensitivity of breast cancer cells to doxorubicin by targeting PTEN. Archives of Medical Research, 42(4), 281–290.PubMedCrossRef
167.
Gong, C., Yao, Y., Wang, Y., Liu, B., Wu, W., Chen, J., et al. (2011). Up-regulation of miR-21 mediates resistance to trastuzumab therapy for breast cancer. Journal of Biological Chemistry, 286(21), 19127–19137.CrossRef
168.
Yu, X., Li, R., Shi, W., Jiang, T., Wang, Y., Li, C., et al. (2016). Silencing of MicroRNA-21 confers the sensitivity to tamoxifen and fulvestrant by enhancing autophagic cell death through inhibition of the PI3K-AKT-mTOR pathway in breast cancer cells. Biomedicine & Pharmacotherapy, 77, 37–44.CrossRef
169.
Wu, Z. H., Tao, Z. H., Zhang, J., Li, T., Ni, C., Xie, J., et al. (2016). MiRNA-21 induces epithelial to mesenchymal transition and gemcitabine resistance via the PTEN/AKT pathway in breast cancer. Tumour Biology, 37(6), 7245–7254.PubMedCrossRef
170.
Yu, L., Yang, Y., Hou, J., Zhai, C., Song, Y., Zhang, Z., et al. (2015). MicroRNA-144 affects radiotherapy sensitivity by promoting proliferation, migration and invasion of breast cancer cells. Oncology Reports, 34(4), 1845–1852.PubMedCrossRef
171.
Liu, T., Guo, J., & Zhang, X. (2019). MiR-202-5p/PTEN mediates doxorubicin-resistance of breast cancer cells via PI3K/Akt signaling pathway. Cancer Biology & Therapy, 20(7), 989–998.CrossRef
172.
Gao, X., Qin, T., Mao, J., Zhang, J., Fan, S., Lu, Y., et al. (2019). PTENP1/miR-20a/PTEN axis contributes to breast cancer progression by regulating PTEN via PI3K/AKT pathway. Journal of Experimental & Clinical Cancer Research, 38(1), 256.CrossRef
173.
Zhong, S., Li, W., Chen, Z., Xu, J., & Zhao, J. (2013). MiR-222 and miR-29a contribute to the drug-resistance of breast cancer cells. Gene, 531(1), 8–14.PubMedCrossRef
174.
Chen, Y., Sun, Y., Chen, L., Xu, X., Zhang, X., Wang, B., et al. (2013). miRNA-200c increases the sensitivity of breast cancer cells to doxorubicin through the suppression of E-cadherin-mediated PTEN/Akt signaling. Molecular Medicine Reports, 7(5), 1579–1584.PubMedCrossRef
175.
Shen, H., Wang, D., Li, L., Yang, S., Chen, X., Zhou, S., et al. (2017). MiR-222 promotes drug-resistance of breast cancer cells to adriamycin via modulation of PTEN/Akt/FOXO1 pathway. Gene, 596, 110–118.PubMedCrossRef
176.
Gu, J., Wang, Y., Wang, X., Zhou, D., Shao, C., Zhou, M., et al. (2018). Downregulation of lncRNA GAS5 confers tamoxifen resistance by activating miR-222 in breast cancer. Cancer Letters, 434, 1–10.PubMedCrossRef
177.
Geng, W., Song, H., Zhao, Q., Dong, K., Pu, Q., Gao, H., et al. (2020). miR-520h stimulates drug resistance to paclitaxel by targeting the OTUD3-PTEN axis in breast cancer. BioMed Research International, 2020, 9512793.PubMedPubMedCentralCrossRef
178.
Sachdeva, M., Wu, H., Ru, P., Hwang, L., Trieu, V., & Mo, Y. Y. (2011). MicroRNA-101-mediated Akt activation and estrogen-independent growth. Oncogene, 30(7), 822–831.PubMedCrossRef
179.
Haga, C. L., Velagapudi, S. P., Strivelli, J. R., Yang, W. Y., Disney, M. D., & Phinney, D. G. (2015). Small molecule inhibition of miR-544 biogenesis disrupts adaptive responses to hypoxia by modulating ATM-mTOR signaling. ACS Chemical Biology, 10(10), 2267–2276.PubMedPubMedCentralCrossRef
180.
Zhang, B., Zhao, R., He, Y., Fu, X., Fu, L., Zhu, Z., et al. (2016). MicroRNA 100 sensitizes luminal A breast cancer cells to paclitaxel treatment in part by targeting mTOR. Oncotarget, 7(5), 5702–5714.PubMedCrossRef
181.
Ma, T., Yang, L., & Zhang, J. (2015). MiRNA5423p downregulation promotes trastuzumab resistance in breast cancer cells via AKT activation. Oncology Reports, 33(3), 1215–1220.PubMedCrossRef
182.
Fu, R., & Tong, J. S. (2020). miR-126 reduces trastuzumab resistance by targeting PIK3R2 and regulating AKT/mTOR pathway in breast cancer cells. Journal of Cellular and Molecular Medicine, 24(13), 7600–7608.PubMedPubMedCentralCrossRef
183.
Pan, X., Hong, X., Lai, J., Cheng, L., Cheng, Y., Yao, M., et al. (2020). Exosomal microRNA-221-3p confers adriamycin resistance in breast cancer cells by targeting PIK3R1. Frontiers in Oncology, 10, 441.PubMedPubMedCentralCrossRef
184.
Vilquin, P., Donini, C. F., Villedieu, M., Grisard, E., Corbo, L., Bachelot, T., et al. (2015). MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer. Breast Cancer Research, 17, 13.PubMedPubMedCentralCrossRef
185.
Dave, B., Mittal, V., Tan, N. M., & Chang, J. C. (2012). Epithelial-mesenchymal transition, cancer stem cells and treatment resistance. Breast Cancer Research, 14(1), 202.PubMedPubMedCentralCrossRef
186.
Shibue, T., & Weinberg, R. A. (2017). EMT, CSCs, and drug resistance: The mechanistic link and clinical implications. Nature Reviews. Clinical Oncology, 14(10), 611–629.PubMedPubMedCentralCrossRef
187.
Smalley, M., Piggott, L., & Clarkson, R. (2013). Breast cancer stem cells: Obstacles to therapy. Cancer Letters, 338(1), 57–62.PubMedCrossRef
188.
Mallini, P., Lennard, T., Kirby, J., & Meeson, A. (2014). Epithelial-to-mesenchymal transition: What is the impact on breast cancer stem cells and drug resistance. Cancer Treatment Reviews, 40(3), 341–348.PubMedCrossRef
189.
Zhou, S., Schuetz, J. D., Bunting, K. D., Colapietro, A. M., Sampath, J., Morris, J. J., et al. (2001). The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nature Medicine, 7(9), 1028–1034.PubMedCrossRef
190.
Dean, M., Fojo, T., & Bates, S. (2005). Tumour stem cells and drug resistance. Nature Reviews Cancer, 5(4), 275–284.PubMedCrossRef
191.
Li, X., Lewis, M. T., Huang, J., Gutierrez, C., Osborne, C. K., Wu, M. F., et al. (2008). Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. Journal of the National Cancer Institute, 100(9), 672–679.PubMedCrossRef
192.
Mani, S. A., Guo, W., Liao, M. J., Eaton, E. N., Ayyanan, A., Zhou, A. Y., et al. (2008). The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell, 133(4), 704–715.PubMedPubMedCentralCrossRef
193.
Pinto, C. A., Widodo, E., Waltham, M., & Thompson, E. W. (2013). Breast cancer stem cells and epithelial mesenchymal plasticity - Implications for chemoresistance. Cancer Letters, 341(1), 56–62.PubMedCrossRef
194.
195.
De Craene, B., & Berx, G. (2013). Regulatory networks defining EMT during cancer initiation and progression. Nature Reviews Cancer, 13(2), 97–110.PubMedCrossRef
196.
Brabletz, S., Bajdak, K., Meidhof, S., Burk, U., Niedermann, G., Firat, E., et al. (2011). The ZEB1/miR-200 feedback loop controls Notch signalling in cancer cells. EMBO Journal, 30(4), 770–782.CrossRef
197.
Burk, U., Schubert, J., Wellner, U., Schmalhofer, O., Vincan, E., Spaderna, S., et al. (2008). A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Reports, 9(6), 582–589.PubMedPubMedCentralCrossRef
198.
Gregory, P. A., Bert, A. G., Paterson, E. L., Barry, S. C., Tsykin, A., Farshid, G., et al. (2008). The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nature Cell Biology, 10(5), 593–601.PubMedCrossRef
199.
Hurteau, G. J., Carlson, J. A., Roos, E., & Brock, G. J. (2009). Stable expression of miR-200c alone is sufficient to regulate TCF8 (ZEB1) and restore E-cadherin expression. Cell Cycle, 8(13), 2064–2069.PubMedCrossRef
200.
Cochrane, D. R., Spoelstra, N. S., Howe, E. N., Nordeen, S. K., & Richer, J. K. (2009). MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents. Molecular Cancer Therapeutics, 8(5), 1055–1066.PubMedPubMedCentralCrossRef
201.
Yang, X., Hu, Q., Hu, L. X., Lin, X. R., Liu, J. Q., Lin, X., et al. (2017). miR-200b regulates epithelial-mesenchymal transition of chemo-resistant breast cancer cells by targeting FN1. Discovery Medicine, 24(131), 75–85.PubMed
202.
Knezevic, J., Pfefferle, A. D., Petrovic, I., Greene, S. B., Perou, C. M., & Rosen, J. M. (2015). Expression of miR-200c in claudin-low breast cancer alters stem cell functionality, enhances chemosensitivity and reduces metastatic potential. Oncogene, 34(49), 5997–6006.PubMedPubMedCentralCrossRef
203.
Li, C. Y., Miao, K. L., Chen, Y., Liu, L. Y., Zhao, G. B., Lin, M. H., et al. (2018). Jagged2 promotes cancer stem cell properties of triple negative breast cancer cells and paclitaxel resistance via regulating microRNA-200. European Review for Medical and Pharmacological Sciences, 22(18), 6008–6014.PubMed
204.
Chen, J., Tian, W., He, H., Chen, F., Huang, J., Wang, X., et al. (2018). Downregulation of miR200c3p contributes to the resistance of breast cancer cells to paclitaxel by targeting SOX2. Oncology Reports, 40(6), 3821–3829.PubMed
205.
Soung YH, Chung H, Yan C, Ju J, Chung J. Arrestin domain containing 3 reverses epithelial to mesenchymal transition and chemo-resistance of TNBC cells by up-regulating expression of miR-200b. Cells 2019; 8(7).
206.
Manavalan TT, Teng Y, Litchfield LM, Muluhngwi P, Al-Rayyan N, Klinge CM. Reduced expression of miR-200 family members contributes to antiestrogen resistance in LY2 human breast cancer cells. PLoS One 2013; 8(4):e62334.
207.
Gao, Y., Zhang, W., Liu, C., & Li, G. (2019). miR-200 affects tamoxifen resistance in breast cancer cells through regulation of MYB. Science and Reports, 9(1), 18844.CrossRef
208.
Tang, H., Song, C., Ye, F., Gao, G., Ou, X., Zhang, L., et al. (2019). miR-200c suppresses stemness and increases cellular sensitivity to trastuzumab in HER2+ breast cancer. Journal of Cellular and Molecular Medicine, 23(12), 8114–8127.PubMedPubMedCentralCrossRef
209.
Song, W., Wu, S., Wu, Q., Zhou, L., Yu, L., Zhu, B., et al. (2019). The microRNA-141-3p/ CDK8 pathway regulates the chemosensitivity of breast cancer cells to trastuzumab. Journal of Cellular Biochemistry, 120(8), 14095–14106.PubMedCrossRef
210.
Chen, J., Tian, W., Cai, H., He, H., & Deng, Y. (2012). Down-regulation of microRNA-200c is associated with drug resistance in human breast cancer. Medical Oncology, 29(4), 2527–2534.PubMedCrossRef
211.
Lee, J. W., Guan, W., Han, S., Hong, D. K., Kim, L. S., & Kim, H. (2018). MicroRNA-708-3p mediates metastasis and chemoresistance through inhibition of epithelial-to-mesenchymal transition in breast cancer. Cancer Science, 109(5), 1404–1413.PubMedPubMedCentralCrossRef
212.
Wang, G., Dong, Y., Liu, H., Ji, N., Cao, J., Liu, A., et al. (2019). Loss of miR-873 contributes to gemcitabine resistance in triple-negative breast cancer via targeting ZEB1. Oncology Letters, 18(4), 3837–3844.PubMedPubMedCentral
213.
Gao, L., Guo, Q., Li, X., Yang, X., Ni, H., Wang, T., et al. (2019). MiR-873/PD-L1 axis regulates the stemness of breast cancer cells. eBioMedicine, 41, 395–407.PubMedPubMedCentralCrossRef
214.
Bockhorn, J., Dalton, R., Nwachukwu, C., Huang, S., Prat, A., Yee, K., et al. (2013). MicroRNA-30c inhibits human breast tumour chemotherapy resistance by regulating TWF1 and IL-11. Nature Communications, 4, 1393.PubMedCrossRef
215.
Guan, X., Gu, S., Yuan, M., Zheng, X., & Wu, J. (2019). MicroRNA-33a-5p overexpression sensitizes triple-negative breast cancer to doxorubicin by inhibiting eIF5A2 and epithelial-mesenchymal transition. Oncology Letters, 18(6), 5986–5994.PubMedPubMedCentral
216.
Luan, Q. X., Zhang, B. G., Li, X. J., & Guo, M. Y. (2016). MiR-129-5p is downregulated in breast cancer cells partly due to promoter H3K27m3 modification and regulates epithelial-mesenchymal transition and multi-drug resistance. European Review for Medical and Pharmacological Sciences, 20(20), 4257–4265.PubMed
217.
Yao, N., Fu, Y., Chen, L., Liu, Z., He, J., Zhu, Y., et al. (2019). Long non-coding RNA NONHSAT101069 promotes epirubicin resistance, migration, and invasion of breast cancer cells through NONHSAT101069/miR-129-5p/Twist1 axis. Oncogene, 38(47), 7216–7233.PubMedCrossRef
218.
Du, F., Yu, L., Wu, Y., Wang, S., Yao, J., Zheng, X., et al. (2019). miR-137 alleviates doxorubicin resistance in breast cancer through inhibition of epithelial-mesenchymal transition by targeting DUSP4. Cell Death & Disease, 10(12), 922.CrossRef
219.
Yan, L., Yang, S., Yue, C. X., Wei, X. Y., Peng, W., Dong, Z. Y., et al. (2020). Long noncoding RNA H19 acts as a miR-340-3p sponge to promote epithelial-mesenchymal transition by regulating YWHAZ expression in paclitaxel-resistant breast cancer cells. Environmental Toxicology, 35(9), 1015–1028.PubMedCrossRef
220.
Shi, S., Chen, X., Liu, H., Yu, K., Bao, Y., Chai, J., et al. (2019). LGR5 acts as a target of miR-340-5p in the suppression of cell progression and drug resistance in breast cancer via Wnt/beta-catenin pathway. Gene, 683, 47–53.PubMedCrossRef
221.
Jiang, L., He, D., Yang, D., Chen, Z., Pan, Q., Mao, A., et al. (2014). MiR-489 regulates chemoresistance in breast cancer via epithelial mesenchymal transition pathway. FEBS Letters, 588(11), 2009–2015.PubMedCrossRef
222.
Dong, H., Hu, J., Zou, K., Ye, M., Chen, Y., Wu, C., et al. (2019). Activation of LncRNA TINCR by H3K27 acetylation promotes trastuzumab resistance and epithelial-mesenchymal transition by targeting microRNA-125b in breast cancer. Molecular Cancer, 18(1), 3.PubMedPubMedCentralCrossRef
223.
Hu, S. H., Wang, C. H., Huang, Z. J., Liu, F., Xu, C. W., Li, X. L., et al. (2016). miR-760 mediates chemoresistance through inhibition of epithelial mesenchymal transition in breast cancer cells. European Review for Medical and Pharmacological Sciences, 20(23), 5002–5008.PubMed
224.
Fu, H., Fu, L., Xie, C., Zuo, W. S., Liu, Y. S., Zheng, M. Z., et al. (2017). miR-375 inhibits cancer stem cell phenotype and tamoxifen resistance by degrading HOXB3 in human ER-positive breast cancer. Oncology Reports, 37(2), 1093–1099.PubMedCrossRef
225.
Ward, A., Balwierz, A., Zhang, J. D., Kublbeck, M., Pawitan, Y., Hielscher, T., et al. (2013). Re-expression of microRNA-375 reverses both tamoxifen resistance and accompanying EMT-like properties in breast cancer. Oncogene, 32(9), 1173–1182.PubMedCrossRef
226.
Zhang, H. D., Sun, D. W., Mao, L., Zhang, J., Jiang, L. H., Li, J., et al. (2015). MiR-139-5p inhibits the biological function of breast cancer cells by targeting Notch1 and mediates chemosensitivity to docetaxel. Biochemical and Biophysical Research Communications, 465(4), 702–713.PubMedCrossRef
227.
Li, X. J., Ji, M. H., Zhong, S. L., Zha, Q. B., Xu, J. J., Zhao, J. H., et al. (2012). MicroRNA-34a modulates chemosensitivity of breast cancer cells to adriamycin by targeting Notch1. Archives of Medical Research, 43(7), 514–521.PubMedCrossRef
228.
Kang, L., Mao, J., Tao, Y., Song, B., Ma, W., Lu, Y., et al. (2015). MicroRNA-34a suppresses the breast cancer stem cell-like characteristics by downregulating Notch1 pathway. Cancer Science, 106(6), 700–708.PubMedPubMedCentralCrossRef
229.
Gong, L. G., Shi, J. C., Shang, J., Hao, J. G., & Du, X. (2019). Effect of miR-34a on resistance to sunitinib in breast cancer by regulating the Wnt/beta-catenin signaling pathway. European Review for Medical and Pharmacological Sciences, 23(3), 1151–1157.PubMed
230.
Palyi-Krekk, Z., Barok, M., Isola, J., Tammi, M., Szollosi, J., & Nagy, P. (2007). Hyaluronan-induced masking of ErbB2 and CD44-enhanced trastuzumab internalisation in trastuzumab resistant breast cancer. European Journal of Cancer, 43(16), 2423–2433.PubMedCrossRef
231.
Boulbes, D. R., Chauhan, G. B., Jin, Q., Bartholomeusz, C., & Esteva, F. J. (2015). CD44 expression contributes to trastuzumab resistance in HER2-positive breast cancer cells. Breast Cancer Research and Treatment, 151(3), 501–513.PubMedCrossRef
232.
Liu, C., Xing, H., Guo, C., Yang, Z., Wang, Y., & Wang, Y. (2019). MiR-124 reversed the doxorubicin resistance of breast cancer stem cells through STAT3/HIF-1 signaling pathways. Cell Cycle, 18(18), 2215–2227.PubMedPubMedCentralCrossRef
233.
Tan, W., Tang, H., Jiang, X., Ye, F., Huang, L., Shi, D., et al. (2019). Metformin mediates induction of miR-708 to inhibit self-renewal and chemoresistance of breast cancer stem cells through targeting CD47. Journal of Cellular and Molecular Medicine, 23(9), 5994–6004.PubMedPubMedCentralCrossRef
234.
Zhou, Y., Hu, Y., Yang, M., Jat, P., Li, K., Lombardo, Y., et al. (2014). The miR-106b~25 cluster promotes bypass of doxorubicin-induced senescence and increase in motility and invasion by targeting the E-cadherin transcriptional activator EP300. Cell Death and Differentiation, 21(3), 462–474.PubMedCrossRef
235.
Hu, Y., Li, K., Asaduzzaman, M., Cuella, R., Shi, H., Raguz, S., et al. (2016). MiR-106b~25 cluster regulates multidrug resistance in an ABC transporter-independent manner via downregulation of EP300. Oncology Reports, 35(2), 1170–1178.PubMedCrossRef
236.
Guarnieri, A. L., Towers, C. G., Drasin, D. J., Oliphant, M. U. J., Andrysik, Z., Hotz, T. J., et al. (2018). The miR-106b-25 cluster mediates breast tumor initiation through activation of NOTCH1 via direct repression of NEDD4L. Oncogene, 37(28), 3879–3893.PubMedPubMedCentralCrossRef
237.
Li, H. Y., Liang, J. L., Kuo, Y. L., Lee, H. H., Calkins, M. J., Chang, H. T., et al. (2017). miR-105/93-3p promotes chemoresistance and circulating miR-105/93-3p acts as a diagnostic biomarker for triple negative breast cancer. Breast Cancer Research, 19(1), 133.PubMedPubMedCentralCrossRef
238.
Chen, Z., Pan, T., Jiang, D., Jin, L., Geng, Y., Feng, X., et al. (2020). The lncRNA-GAS5/miR-221-3p/DKK2 axis modulates ABCB1-mediated adriamycin resistance of breast cancer via the Wnt/beta-catenin signaling pathway. Mol Ther Nucleic Acids, 19, 1434–1448.PubMedPubMedCentralCrossRef
239.
Tang, T., Cheng, Y., She, Q., Jiang, Y., Chen, Y., Yang, W., et al. (2018). Long non-coding RNA TUG1 sponges miR-197 to enhance cisplatin sensitivity in triple negative breast cancer. Biomedicine & Pharmacotherapy, 107, 338–346.CrossRef
240.
Wu, D., Zhang, J., Lu, Y., Bo, S., Li, L., Wang, L., et al. (2019). miR-140-5p inhibits the proliferation and enhances the efficacy of doxorubicin to breast cancer stem cells by targeting Wnt1. Cancer Gene Therapy, 26(3–4), 74–82.PubMedCrossRef
241.
Yu, Y., Yin, W., Yu, Z. H., Zhou, Y. J., Chi, J. R., Ge, J., et al. (2019). miR-190 enhances endocrine therapy sensitivity by regulating SOX9 expression in breast cancer. Journal of Experimental & Clinical Cancer Research, 38(1), 22.CrossRef
242.
Jia, Z., Zhu, H., Sun, H., Hua, Y., Zhang, G., Jiang, J., et al. (2020). Adipose mesenchymal stem cell-derived exosomal microRNA-1236 reduces resistance of breast cancer cells to cisplatin by suppressing SLC9A1 and the Wnt/beta-catenin signaling. Cancer Manag Res, 12, 8733–8744.PubMedPubMedCentralCrossRef
243.
Liang, Y., Song, X., Li, Y., Su, P., Han, D., Ma, T., et al. (2019). circKDM4C suppresses tumor progression and attenuates doxorubicin resistance by regulating miR-548p/PBLD axis in breast cancer. Oncogene, 38(42), 6850–6866.PubMedCrossRef
244.
Wang YY, Yan L, Yang S, Xu HN, Chen TT, Dong ZY, et al. Long noncoding RNA AC073284.4 suppresses epithelial-mesenchymal transition by sponging miR-18b-5p in paclitaxel-resistant breast cancer cells. J Cell Physiol 2019; 234(12):23202–23215.
245.
Santos, J. C., Lima, N. D. S., Sarian, L. O., Matheu, A., Ribeiro, M. L., & Derchain, S. F. M. (2018). Exosome-mediated breast cancer chemoresistance via miR-155 transfer. Science and Reports, 8(1), 829.CrossRef
246.
Yang, L. W., Wu, X. J., Liang, Y., Ye, G. Q., Che, Y. C., Wu, X. Z., et al. (2020). miR-155 increases stemness and decitabine resistance in triple-negative breast cancer cells by inhibiting TSPAN5. Molecular Carcinogenesis, 59(4), 447–461.PubMedCrossRef
247.
Chu, S., Liu, G., Xia, P., Chen, G., Shi, F., Yi, T., et al. (2017). miR-93 and PTEN: Key regulators of doxorubicin-resistance and EMT in breast cancer. Oncology Reports, 38(4), 2401–2407.PubMedCrossRef
248.
Duan, X., Liu, X., Cao, Y., Li, Y., Silayiding, A., Zhang, L., et al. (2021). Effect of microRNA-766 promotes proliferation, chemoresistance, migration, and invasion of breast cancer cells. Clinical Breast Cancer, 21(1), e1–e17.PubMedCrossRef
249.
De Mattos-Arruda, L., Bottai, G., Nuciforo, P. G., Di Tommaso, L., Giovannetti, E., Peg, V., et al. (2015). MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients. Oncotarget, 6(35), 37269–37280.PubMedPubMedCentralCrossRef
250.
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002). Multidrug resistance in cancer: Role of ATP-dependent transporters. Nature Reviews Cancer, 2(1), 48–58.PubMedCrossRef
251.
Zhu, X., Li, Y., Shen, H., Li, H., Long, L., Hui, L., et al. (2013). miR-137 restoration sensitizes multidrug-resistant MCF-7/ADM cells to anticancer agents by targeting YB-1. Acta Biochimica et Biophysica Sinica (Shanghai), 45(2), 80–86.CrossRef
252.
Bao, L., Hazari, S., Mehra, S., Kaushal, D., Moroz, K., & Dash, S. (2012). Increased expression of P-glycoprotein and doxorubicin chemoresistance of metastatic breast cancer is regulated by miR-298. American Journal of Pathology, 180(6), 2490–2503.CrossRef
253.
Kovalchuk, O., Filkowski, J., Meservy, J., Ilnytskyy, Y., Tryndyak, V. P., Chekhun, V. F., et al. (2008). Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Molecular Cancer Therapeutics, 7(7), 2152–2159.PubMedCrossRef
254.
Thorne, J. L., Battaglia, S., Baxter, D. E., Hayes, J. L., Hutchinson, S. A., Jana, S., et al. (2018). MiR-19b non-canonical binding is directed by HuR and confers chemosensitivity through regulation of P-glycoprotein in breast cancer. Biochimica et Biophysica Acta, Gene Regulatory Mechanisms, 1861(11), 996–1006.PubMedCrossRef
255.
He, D. X., Gu, X. T., Jiang, L., Jin, J., & Ma, X. (2014). A methylation-based regulatory network for microRNA 320a in chemoresistant breast cancer. Molecular Pharmacology, 86(5), 536–547.PubMedCrossRef
256.
Wang, R., Zhang, T., Yang, Z., Jiang, C., & Seng, J. (2018). Long non-coding RNA FTH1P3 activates paclitaxel resistance in breast cancer through miR-206/ABCB1. Journal of Cellular and Molecular Medicine, 22(9), 4068–4075.PubMedPubMedCentralCrossRef
257.
Yi, D., Xu, L., Wang, R., Lu, X., & Sang, J. (2019). miR-381 overcomes cisplatin resistance in breast cancer by targeting MDR1. Cell Biology International, 43(1), 12–21.PubMedCrossRef
258.
Chen, X., Wang, Y. W., & Gao, P. (2018). SPIN1, negatively regulated by miR-148/152, enhances Adriamycin resistance via upregulating drug metabolizing enzymes and transporter in breast cancer. Journal of Experimental & Clinical Cancer Research, 37(1), 100.CrossRef
259.
Moody, H. L., Lind, M. J., & Maher, S. G. (2017). MicroRNA-31 regulates chemosensitivity in malignant pleural mesothelioma. Mol Ther Nucleic Acids, 8, 317–329.PubMedPubMedCentralCrossRef
260.
Dong, Z., Zhong, Z., Yang, L., Wang, S., & Gong, Z. (2014). MicroRNA-31 inhibits cisplatin-induced apoptosis in non-small cell lung cancer cells by regulating the drug transporter ABCB9. Cancer Letters, 343(2), 249–257.PubMedCrossRef
261.
Gong, J. P., Yang, L., Tang, J. W., Sun, P., Hu, Q., Qin, J. W., et al. (2016). Overexpression of microRNA-24 increases the sensitivity to paclitaxel in drug-resistant breast carcinoma cell lines via targeting ABCB9. Oncology Letters, 12(5), 3905–3911.PubMedPubMedCentralCrossRef
262.
Pogribny, I. P., Filkowski, J. N., Tryndyak, V. P., Golubov, A., Shpyleva, S. I., & Kovalchuk, O. (2010). Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin. International Journal of Cancer, 127(8), 1785–1794.PubMedCrossRef
263.
Liang, Z., Wu, H., Xia, J., Li, Y., Zhang, Y., Huang, K., et al. (2010). Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1. Biochemical Pharmacology, 79(6), 817–824.PubMedCrossRef
264.
Lu, L., Ju, F., Zhao, H., & Ma, X. (2015). MicroRNA-134 modulates resistance to doxorubicin in human breast cancer cells by downregulating ABCC1. Biotechnology Letters, 37(12), 2387–2394.PubMedCrossRef
265.
Chang, L., Hu, Z., Zhou, Z., & Zhang, H. (2018). Linc00518 contributes to multidrug resistance through regulating the MiR-199a/MRP1 axis in breast cancer. Cellular Physiology and Biochemistry, 48(1), 16–28.PubMedCrossRef
266.
Zeng C, Fan D, Xu Y, Li X, Yuan J, Yang Q, et al. Curcumol enhances the sensitivity of doxorubicin in triple-negative breast cancer via regulating the miR-181b-2–3p-ABCC3 axis. Biochem Pharmacol 2020; 174:113795.
267.
Russel, F. G., Koenderink, J. B., & Masereeuw, R. (2008). Multidrug resistance protein 4 (MRP4/ABCC4): A versatile efflux transporter for drugs and signalling molecules. Trends in Pharmacological Sciences, 29(4), 200–207.PubMedCrossRef
268.
Hu, D., Li, M., Su, J., Miao, K., & Qiu, X. (2019). Dual-targeting of miR-124-3p and ABCC4 promotes sensitivity to adriamycin in breast cancer cells. Genetic Testing and Molecular Biomarkers, 23(3), 156–165.PubMedCrossRef
269.
Jedlitschky, G., Burchell, B., & Keppler, D. (2000). The multidrug resistance protein 5 functions as an ATP-dependent export pump for cyclic nucleotides. Journal of Biological Chemistry, 275(39), 30069–30074.CrossRef
270.
Masri, S., Liu, Z., Phung, S., Wang, E., Yuan, Y. C., & Chen, S. (2010). The role of microRNA-128a in regulating TGFbeta signaling in letrozole-resistant breast cancer cells. Breast Cancer Research and Treatment, 124(1), 89–99.PubMedPubMedCentralCrossRef
271.
Jiao, X., Zhao, L., Ma, M., Bai, X., He, M., Yan, Y., et al. (2013). MiR-181a enhances drug sensitivity in mitoxantone-resistant breast cancer cells by targeting breast cancer resistance protein (BCRP/ABCG2). Breast Cancer Research and Treatment, 139(3), 717–730.PubMedCrossRef
272.
Pan, Y. Z., Morris, M. E., & Yu, A. M. (2009). MicroRNA-328 negatively regulates the expression of breast cancer resistance protein (BCRP/ABCG2) in human cancer cells. Molecular Pharmacology, 75(6), 1374–1379.PubMedPubMedCentralCrossRef
273.
Ma, M. T., He, M., Wang, Y., Jiao, X. Y., Zhao, L., Bai, X. F., et al. (2013). MiR-487a resensitizes mitoxantrone (MX)-resistant breast cancer cells (MCF-7/MX) to MX by targeting breast cancer resistance protein (BCRP/ABCG2). Cancer Letters, 339(1), 107–115.PubMedCrossRef
274.
Wang, Y., Zhao, L., Xiao, Q., Jiang, L., He, M., Bai, X., et al. (2016). miR-302a/b/c/d cooperatively inhibit BCRP expression to increase drug sensitivity in breast cancer cells. Gynecologic Oncology, 141(3), 592–601.PubMedCrossRef
275.
Takahashi, R. U., Miyazaki, H., Takeshita, F., Yamamoto, Y., Minoura, K., Ono, M., et al. (2015). Loss of microRNA-27b contributes to breast cancer stem cell generation by activating ENPP1. Nature Communications, 6, 7318.PubMedCrossRef
276.
Pan, X., Yang, X., Zang, J., Zhang, S., Huang, N., Guan, X., et al. (2017). Downregulation of eIF4G by microRNA-503 enhances drug sensitivity of MCF-7/ADR cells through suppressing the expression of ABC transport proteins. Oncology Letters, 13(6), 4785–4793.PubMedPubMedCentralCrossRef
277.
Smolle, M. A., Calin, H. N., Pichler, M., & Calin, G. A. (2017). Noncoding RNAs and immune checkpoints-clinical implications as cancer therapeutics. FEBS Journal, 284(13), 1952–1966.CrossRef
278.
Rupaimoole, R., & Slack, F. J. (2017). MicroRNA therapeutics: Towards a new era for the management of cancer and other diseases. Nature Reviews. Drug Discovery, 16(3), 203–222.PubMedCrossRef
Metadata
Title
MicroRNAs as a clue to overcome breast cancer treatment resistance
Authors
Iris Garrido-Cano
Birlipta Pattanayak
Anna Adam-Artigues
Ana Lameirinhas
Sandra Torres-Ruiz
Eduardo Tormo
Raimundo Cervera
Pilar Eroles
Publication date
01-03-2022
Publisher
Springer US
Published in
Cancer and Metastasis Reviews / Issue 1/2022
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-021-09992-0

Other articles of this Issue 1/2022

Cancer and Metastasis Reviews 1/2022 Go to the issue

COMMENTARY

COVID-19 and cancer: start the resolution!

Non-Thematic Review

Lipid metabolism reprogramming in renal cell carcinoma

CLINICAL

Adipocytokines and disease progression in endometrial cancer: a systematic review

Non-Thematic Review

Of vascular defense, hemostasis, cancer, and platelet biology: an evolutionary perspective

Non-Thematic Review

Glycosylation as a regulator of site-specific metastasis

Non-Thematic Review

Emerging roles of epithelial-mesenchymal plasticity in invasion-metastasis cascade and therapy resistance
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits